Therapeutic Potential of Kappa Opioid Agonists
AbstractMany original research articles have been published that describe findings and outline areas for the development of kappa-opioid agonists (KOAs) as novel drugs; however, a single review article that summarizes the broad potential for KOAs in drug development does not exist. It is well-established that KOAs demonstrate efficacy in pain attenuation; however, KOAs also have proven to be beneficial in treating a variety of novel but often overlapping conditions including cardiovascular disease, pruritus, nausea, inflammatory diseases, spinal anesthesia, stroke, hypoxic pulmonary hypertension, multiple sclerosis, addiction, and post-traumatic cartilage degeneration. This article summarizes key findings of KOAs and discusses the untapped therapeutic potential of KOAs in the treatment of many human diseases. View Full-Text
Share & Cite This Article
Beck, T.C.; Hapstack, M.A.; Beck, K.R.; Dix, T.A. Therapeutic Potential of Kappa Opioid Agonists. Pharmaceuticals 2019, 12, 95.
Beck TC, Hapstack MA, Beck KR, Dix TA. Therapeutic Potential of Kappa Opioid Agonists. Pharmaceuticals. 2019; 12(2):95.Chicago/Turabian Style
Beck, Tyler C.; Hapstack, Matthew A.; Beck, Kyle R.; Dix, Thomas A. 2019. "Therapeutic Potential of Kappa Opioid Agonists." Pharmaceuticals 12, no. 2: 95.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.